Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

12/15/2025

We are a biopharmaceutical company dedicated to advancing our proprietary technology platforms to address multiple high-value cancer indications and unlock new possibilities in oncology.

12/11/2025

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

https://bit.ly/4q3qkZq

12/09/2025

We remain focused on advancing our development strategy through strong institutional partnerships.

If you’re interested in collaborating with Xenetic Bio, please reach out to us at info@xeneticbio.com

12/04/2025

Our lead program has the potential to elevate current cancer treatment approaches and advance options for patients.

Learn more: https://bit.ly/48kraJS

11/19/2025

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

https://bit.ly/4pmRTNd

11/18/2025

Our lead program aims to overcome T cell exclusion and immunosuppressive signals in the tumor microenvironment, unlocking new possibilities in cancer treatment and bringing hope to patients who need it most.

11/13/2025

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

https://bit.ly/3LZZClC

11/10/2025

: Early detection of remains a major challenge. Most patients are diagnosed at advanced stages, leading to a five-year survival rate of only about 3%. We’re working to help change that.

11/04/2025

November is , a time to honor patients, families and researchers driving progress. Together, we can make a difference in the fight against this devastating disease.

Learn more: https://bit.ly/45CsODB

10/30/2025

At , we’re developing a proprietary technology platform to boost the power of immunotherapies, potentially unlocking new possibilities in cancer treatment and driving better outcomes for patients.

10/21/2025

We are focused on advancing our proprietary technology platform to address multiple high-value cancer indications.

10/16/2025

Our oncology platform is built with one goal: to make cancer treatments more effective. With the potential to target multiple indications, we’re working to change outcomes and bring new hope to patients.

Find out more: https://bit.ly/3PkEMfi

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Want your practice to be the top-listed Clinic in Framingham?

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.